New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

How would you treat a patient with stage IE gastric MALT lymphoma with negative testing for H. pylori?

1 Answers

Mednet MemberInvited Expert
Radiation Oncology · University Hospital Basel

Standard of care treatment in these patients mostly includes local radiotherapy. You need to be certain that the patient is truly HP-negative; the gold standard for this is negative histopathology for HP. In patients with negative HP histology, you should still rule out HP with non-invasive measures...

Do you use particular cutoffs of troponin and BNP that you deem indicative of a hemodynamically significant/high-risk PE, or do you see any abnormal value as indicative?

2
1 Answers

Mednet MemberInvited Expert
Cardiology · Mount Sinai Heart

Biomarkers are contributory variables in a multivariable assessment of any patient with pulmonary embolism. In light of the multiple factors that influence biomarker levels in a given patient, it is challenging to define one-size-fits-all cut points for meaning. It is also important to recognize tha...

How will you utilize the PARADIGM study results from ASH 2025, comparing azacitidine/venetoclax to intensive induction chemotherapy for fit patients with newly diagnosed AML?

1
1 Answers

Mednet MemberInvited Expert
Hematology · University of Chicago

It was very exciting to see PARADIGM presented as a plenary at ASH, and I look forward to the manuscript! Interpreting the findings in the context of the enrolled patients is very important. The median age of enrolled patients was approximately 65 years in both arms, and ~75% of enrolled patients ha...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

In patients with inflammatory arthritis (RA, psoriatic arthritis) and a history of MGUS are there any concerns regarding use of biologics?

1
1 Answers

Mednet Member
Rheumatology · Rheumatology Associates of Long Island

There is no absolute contraindication to any particular biologic used to manage active RA in a patient with MGUS. The literature does point out a small potential risk associated with tocilizumab in terms of development of myeloma influenced by the IL-6 pathway (and I would tend to extend that potent...

How do you manage catheter-associated, upper extremity superficial venous thrombosis?

1
1 Answers

Mednet MemberInvited Expert
Hematology · Oregon Health & Science University

I manage catheter-associated upper extremity superficial venous thrombosis (SVT) conservatively with arm elevation, warm compresses, NSAIDs, and topical creams containing NSAIDs. Upper extremity SVT is primarily caused by indwelling intravenous catheters, so I do strongly recommend catheter removal ...

How do you explain the use of an AI scribe to patients the first time it is used in their care?

14
5 Answers

Mednet MemberInvited Expert
Psychiatry · University of Maryland School of Medicine

I use an AI scribe in my outpatient clinic, and around 90–95% of my patients agree to it. I obtain consent at the start of each visit and make it clear that it's completely optional—that they can say no at the start or change their mind at any point in the visit, with no impact on their care. I also...

How do you utilize lenalidomide maintenance in non-transplant eligible myeloma?

6
3 Answers

Mednet MemberInvited Expert
Medical Oncology · OhioHealth

Maintenance is a standard of care management for both transplant eligible and transplant ineligible, regardless of type of induction regimen. Studies have shown benefit for both groups. Time to progression (PFS) almost twice as long for both groups with maintenance compared to no maintenance. - For ...

Following the ECHO trial, are you routinely incorporating acalabrutinib plus bendamustine-rituximab into your frontline treatment approach for patients with MCL?

3 Answers

Mednet Member
Medical Oncology · IHA Hem Onc Consult

This is a question with multiple correct answers. I use the following principles in making my decision: BR is an excellent “backbone” induction regimen in any age group. Cytarabine is the main drug in the more aggressive induction regimens used in younger patients. Induction chemotherapy achieves h...

Do you consider co-prescribing hormone therapy and anticoagulation in a patient with prior DVT and uncontrollable VSM uncontrolled by non-hormonal therapies?

3
4 Answers

Mednet MemberInvited Expert
Hematology · Gundersen Health

While I agree that you need to be thoughtful about adding additional VTE risk to patients with a history of VTE, I am much less concerned when patients are already on full-dose anticoagulation. Especially when the medication is transdermal estrogen, which has the lowest effect on thrombotic risk. I ...

How would you manage a patient with HbSS and severe pulmonary hypertension on home oxygen?

1
1 Answers

Mednet MemberInvited Expert
Hematology · Boston University School of Medicine

This patient should be referred to a specialist in pulmonary hypertension in sickle cell disease for right heart catheterization and aggressive management of the pulmonary hypertension. As described, the patient is not a good candidate for lung transplant or gene therapy.